John E. Imhoff - 06 Mar 2025 Form 4/A - Amendment Insider Report for GUIDED THERAPEUTICS INC (GTHP)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: GTHP
Reported as of: 06 Mar 2025
Net transaction value: +$2,813,007
SEC form: 4/A - Amendment
Accepted by SEC: 23 May 2025, 14:16:41 UTC
Original report date: 17 Apr 2025
Prior SEC filing: 18 Feb 2025
Next SEC filing: 12 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ John E. Imhoff

Key filing fact

John E. Imhoff filed Form 4/A - Amendment for GUIDED THERAPEUTICS INC (GTHP) on 23 May 2025.

Key facts

This page summarizes John E. Imhoff's Form 4/A - Amendment filing for GUIDED THERAPEUTICS INC (GTHP).
13 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 May 2025, 14:16.

Change

Previous filing in this sequence was filed on 18 Feb 2025.
Current net transaction value: +$2,813,007.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001348439 Primary reporting owner

Imhoff John E

Relationship: Director, 10%+ Owner
Address: 5853 PEACHTREE CORNERS EAST, SUITE B, PEACHTREE CORNERS
Signature: /s/ John E. Imhoff
Signature date: 23 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GTHP transaction

Preferred Series D Stock

Other

Transaction value
Shares: -300
Change %: -100%
Price
Shares after: 0
Date: 06 Mar 2025
Ownership: Direct
Footnotes: F1

GTHP transaction

Common Stock

Other

Transaction value
Shares: +900,000
Change %: +10%
Price
Shares after: 9,662,756
Date: 06 Mar 2025
Ownership: Direct
Footnotes: F1

GTHP transaction

Preferred Series C2 Stock

Other

Transaction value
Shares: -2,401
Change %: -100%
Price
Shares after: 0
Date: 06 Mar 2025
Ownership: Direct
Footnotes: F2

GTHP transaction

Common Stock

Other

Transaction value: $2,400,750
Shares: +4,801,500
Change %: +50%
Price: $0.5000
Shares after: 14,464,256
Date: 06 Mar 2025
Ownership: Direct

GTHP transaction

Preferred Series C Stock

Purchase

Transaction value
Shares: +286
Change %
Price
Shares after: 286
Date: 07 Mar 2025
Ownership: Direct
Footnotes: F3

GTHP transaction

Preferred Series C Stock

Other

Transaction value
Shares: -286
Change %: -100%
Price
Shares after: 0
Date: 11 Mar 2025
Ownership: Direct
Footnotes: F3

GTHP transaction

Common Stock

Other

Transaction value: $285,950
Shares: +2,258,690
Change %: +16%
Price: $0.1266
Shares after: 16,722,946
Date: 11 Mar 2025
Ownership: Direct

GTHP transaction

Preferred Series E Stock

Purchase

Transaction value
Shares: +150
Change %: +60%
Price
Shares after: 400
Date: 13 Mar 2025
Ownership: Direct
Footnotes: F4

GTHP transaction

Common Stock

Purchase

Transaction value: $100,000
Shares: +1,000,000
Change %: +6%
Price: $0.1000
Shares after: 17,722,946
Date: 18 Mar 2025
Ownership: Direct
Footnotes: F5

GTHP transaction

Common Stock

Purchase

Transaction value: $26,307
Shares: +263,069
Change %: +1.5%
Price: $0.1000
Shares after: 17,986,015
Date: 18 Mar 2025
Ownership: Direct
Footnotes: F6

GTHP transaction

Common Stock

Other

Transaction value
Shares: +6,365
Change %: +0.04%
Price
Shares after: 17,992,380
Date: 10 Apr 2025
Ownership: Direct
Footnotes: F7

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GTHP transaction Derivative

Warrants

Purchase

Transaction value
Shares: +1,000,000
Change %
Price
Shares after: 1,000,000
Date: 18 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,000,000
Exercise price: $0.1300
Footnotes: F5

GTHP transaction Derivative

Warrants

Purchase

Transaction value
Shares: +263,069
Change %: +26%
Price
Shares after: 1,263,069
Date: 18 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 263,069
Exercise price: $0.1300
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price.

Footnote F2

On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares.

Footnote F3

On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares.

Footnote F4

On March 13, 2025, for a purchase price of $30,000, Mr. Imhoff purchased 150 shares of Series E preferred stock from a third party. The shares have a conversion price of $0.25 and a stated value of $1,000.

Footnote F5

In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above.

Footnote F6

These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943.

Footnote F7

These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943.